Universal health coverage (EB152)
On 1 February 2023, IFPMA attended the 152nd session of the Executive Board at the World Health Organization in Geneva. IFPMA delivered a statement for the agenda item related to universal health coverage.
COVID-19 has highlighted the link between UHC and global health security and brought broad recognition that chronic conditions and pandemics constitute a “perfect storm” that requires building strong and resilient health systems and increasing health equity, all of which requires robust domestic financing.
UHC is the primary responsibility of governments. It is clear that no single government, organization, or sector can achieve UHC on its own, particularly when countries are facing an unparalleled combination of external shocks. Integrating lessons from recent crises, including the COVID-19 pandemic, will bolster the UHC agenda. We support governments to prioritize prevention, treatment, and care in essential benefits packages for NCDs and communicable diseases such as HIV, with primary healthcare being the foundation of UHC. The innovative pharmaceutical industry stands with the global health community to support countries in accelerating efforts to achieve UHC.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
